Novel anti-silicone surface-associated antigen antibodies (anti-SSAA(x)) may help differentiate symptomatic patients with silicone breast implants from patients with classical rheumatological disease.

The frequency of novel autoreactive antibodies to silicone surface associated antigens (anti-SSAA(x)) was measured in healthy control patients, symptomatic patients with breast implants, asymptomatic patients with breast implants, and control patients with classical rheumatological diseases. The frequencies of elevated anti-SSAA(x) antibodies in 310 symptomatic breast implant patients were 17.4% anti-SSAA(fn), 12.9% anti-SSAA(col1), and 7.4% anti-SSAA(col3) and 7.1% anti-SSAA(fbgn) [Normal (n = 173) = 0.6% for all four tests] (p < .005). In 11 asymptomatic breast implant patients, the frequencies of elevated values for the same anti-SSAA's were 0%, 9%, 0%, and 0% respectively, while in 50 patients with rheumatoid arthritis, the frequencies were 4%, 0%, 6% and 2% respectively. The anti-SSAA(x) profile for symptomatic patients with breast implants was different than the profile for control healthy patients (p < .005 on all eight tests) but differed significantly by two measures, anti-SSAA(fbgn) and anti-SSAA(col3), from the profile for the 19 patients with systemic lupus erythematosus. We conclude that anti-SSAA(x) antibodies levels in symptomatic patients with breast implants are elevated, that the antibodies are associated with symptoms, and that they differ both qualitatively and quantitatively from healthy controls, asymptomatic patients with breast implants, and symptomatic patients with classical rheumatological diseases.